×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IBRX – immunitybio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IBRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
05:27 am
ibrx
ImmunityBio and nCartes partner to automate clinical trial data processes [Yahoo! Finance]
Low
Report
ImmunityBio and nCartes partner to automate clinical trial data processes [Yahoo! Finance]
11/21
10:07 am
ibrx
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
Medium
Report
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]
11/21
10:00 am
ibrx
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
Low
Report
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
11/19
11:53 am
ibrx
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet [Yahoo! Finance]
11/19
09:00 am
ibrx
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
Medium
Report
ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements
11/19
08:20 am
ibrx
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months [Yahoo! Finance]
Medium
Report
ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months [Yahoo! Finance]
11/19
08:00 am
ibrx
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
Medium
Report
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
11/14
08:08 am
ibrx
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon [Globe and Mail, The (Toronto, Canada)]
Low
Report
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon [Globe and Mail, The (Toronto, Canada)]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
08:02 am
ibrx
Form 8-K ImmunityBio, Inc. For: Nov 19
Medium
Report
Form 8-K ImmunityBio, Inc. For: Nov 19
11/12
09:33 am
ibrx
Form 8-K ImmunityBio, Inc. For: Nov 12
Medium
Report
Form 8-K ImmunityBio, Inc. For: Nov 12
11/12
09:25 am
ibrx
Form 10-Q ImmunityBio, Inc. For: Sep 30
Medium
Report
Form 10-Q ImmunityBio, Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: